Brown Advisory Securities LLC Has $1.38 Million Position in Pfizer Inc. (NYSE:PFE)

Brown Advisory Securities LLC reduced its holdings in Pfizer Inc. (NYSE:PFEGet Rating) by 8.5% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 26,683 shares of the biopharmaceutical company’s stock after selling 2,492 shares during the period. Brown Advisory Securities LLC’s holdings in Pfizer were worth $1,379,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Norges Bank acquired a new stake in Pfizer in the 4th quarter worth about $3,351,891,000. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main increased its position in Pfizer by 577.8% during the 4th quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 12,247,903 shares of the biopharmaceutical company’s stock worth $715,270,000 after purchasing an additional 10,440,786 shares in the last quarter. Coatue Management LLC acquired a new position in Pfizer during the 4th quarter worth approximately $608,919,000. Darwin Global Management Ltd. bought a new stake in Pfizer during the 4th quarter worth approximately $454,553,000. Finally, Los Angeles Capital Management LLC grew its holdings in Pfizer by 1,080.2% during the 1st quarter. Los Angeles Capital Management LLC now owns 8,200,204 shares of the biopharmaceutical company’s stock worth $424,525,000 after acquiring an additional 7,505,371 shares during the last quarter. 66.50% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

PFE has been the topic of a number of analyst reports. SVB Leerink reduced their price objective on shares of Pfizer from $55.00 to $53.00 and set a “market perform” rating on the stock in a research note on Friday, July 29th. The Goldman Sachs Group set a $50.00 price objective on shares of Pfizer in a report on Friday, July 29th. Morgan Stanley lowered their target price on shares of Pfizer from $52.00 to $49.00 and set an “equal weight” rating for the company in a report on Friday, July 8th. Wells Fargo & Company reduced their price target on shares of Pfizer from $60.00 to $55.00 in a research report on Wednesday, May 4th. Finally, Barclays increased their price target on shares of Pfizer from $50.00 to $52.00 and gave the company an “equal weight” rating in a research report on Monday. Nine investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Pfizer presently has an average rating of “Moderate Buy” and a consensus target price of $57.50.

Pfizer Stock Down 1.0 %

Shares of Pfizer stock traded down $0.48 during trading on Friday, hitting $49.38. 413,882 shares of the stock traded hands, compared to its average volume of 16,919,380. The firm has a market cap of $277.07 billion, a P/E ratio of 9.77, a price-to-earnings-growth ratio of 0.61 and a beta of 0.67. The company has a current ratio of 1.39, a quick ratio of 1.13 and a debt-to-equity ratio of 0.43. Pfizer Inc. has a 52-week low of $40.94 and a 52-week high of $61.71. The stock’s fifty day simple moving average is $51.18 and its 200 day simple moving average is $51.14.

Pfizer (NYSE:PFEGet Rating) last issued its quarterly earnings data on Thursday, July 28th. The biopharmaceutical company reported $2.04 earnings per share for the quarter, beating analysts’ consensus estimates of $1.95 by $0.09. The company had revenue of $27.74 billion for the quarter, compared to the consensus estimate of $26.20 billion. Pfizer had a return on equity of 44.38% and a net margin of 28.92%. The firm’s revenue for the quarter was up 46.8% compared to the same quarter last year. During the same quarter last year, the company earned $1.07 earnings per share. On average, equities analysts predict that Pfizer Inc. will post 6.54 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 6th. Investors of record on Wednesday, June 29th will be given a dividend of $0.40 per share. This represents a $1.60 annualized dividend and a yield of 3.24%. The ex-dividend date of this dividend is Thursday, July 28th. Pfizer’s dividend payout ratio is currently 31.31%.

Insider Activity at Pfizer

In other news, EVP William R. Carapezzi, Jr. sold 32,908 shares of the business’s stock in a transaction that occurred on Thursday, May 12th. The stock was sold at an average price of $50.00, for a total value of $1,645,400.00. Following the completion of the sale, the executive vice president now directly owns 38,146 shares in the company, valued at $1,907,300. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, SVP Jennifer B. Damico sold 4,218 shares of Pfizer stock in a transaction that occurred on Tuesday, June 7th. The stock was sold at an average price of $53.96, for a total value of $227,603.28. Following the sale, the senior vice president now directly owns 10,846 shares of the company’s stock, valued at $585,250.16. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP William R. Carapezzi, Jr. sold 32,908 shares of Pfizer stock in a transaction that occurred on Thursday, May 12th. The stock was sold at an average price of $50.00, for a total value of $1,645,400.00. Following the completion of the sale, the executive vice president now directly owns 38,146 shares in the company, valued at $1,907,300. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 41,126 shares of company stock worth $2,075,003. 0.05% of the stock is owned by corporate insiders.

Pfizer Company Profile

(Get Rating)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.

See Also

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFEGet Rating).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.